NeoStem Announces Participation In Multiple September Conferences
NEW YORK, Sept. 8, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced it is presenting at three upcoming September conferences: the Rodman & Renshaw Annual Healthcare Conference, the Cell Therapy Commercialization Summit, and the JMP Securities Healthcare Conference.
"NeoStem's strategic combination of revenues with manufacturing and a global reach has positioned the Company to be a leader in the cell therapy space and we are pleased to share NeoStem updates with industry and the investor community," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. NeoStem will be presenting at the following conferences:
Rodman & Renshaw 13th Annual Healthcare Conference - September 11-13, New York, New York
11:15 AM on Monday, September 12 at the Waldorf Astoria, New York, NY in the Starlight North room.
Cell Therapy Commercialization Summit - September 19-21, Boston, MA 11 AM on Monday, September 19 as part of the Cell Therapy Investor Forum, located in the Seaport World Trade Center. 1:45 PM and 4:30 PM on Tuesday, September 20. 6th Annual JMP Securities Healthcare Conference - September 27-29, New York, New York Wednesday, September 28 at 9 AM at the St. Regis Hotel, New York, NY. About NeoStem, Inc. NeoStem is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January, 2011 acquisition of Progenitor Cell Therapy, and its July 13, 2011 agreement to acquire Amorcyte, Inc. (which is expected to close in the fourth quarter subject to shareholder approval) position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. PCT not only gives NeoStem access to a world class contract manufacturing cell therapy company, but provides NeoStem a platform and expertise around the evaluation, development and regulatory requirements necessary to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
